Elanco launches Befrena for canine allergic itch: full analysis

Elanco is moving deeper into canine dermatology with the phased U.S. launch of Befrena, a tirnovetmab injection for dogs with allergic dermatitis and canine atopic dermatitis. The product received USDA approval on December 31, 2025, and Elanco announced on May 18, 2026, that launch activity is now underway, with select veterinarians already using the product in clinics through an Early Experience Program. Elanco says Befrena targets IL-31, a cytokine involved in itch signaling, and is designed to begin controlling itch within 24 hours. (elanco.com)

The launch builds on a broader push by Elanco to strengthen its dermatology business. Befrena is the company’s second dermatology product approved in less than two years, following Zenrelia, and Elanco’s annual report said it expected Befrena to launch in the second quarter of 2026. That timing matters because canine dermatology remains one of the most commercially important companion animal categories, and Elanco has framed the U.S. market at about $1.3 billion. (elanco.com)

Regulatory documents add useful detail beyond the launch messaging. USDA APHIS lists tirnovetmab as product code 958005 for canine use, and the agency’s product compilation summary describes multiple studies supporting licensure. In an IL-31-induced pruritus model, dogs receiving the product had markedly lower pruritus scores than placebo-treated dogs after challenge. In a field efficacy study, 213 client-owned dogs were enrolled across 14 veterinary practices, and by day 56, 24% of product-treated dogs had been withdrawn for lack of efficacy or prohibited medication use versus 44% of controls. The same USDA summary also describes a 400-dog field safety study in which dogs received three doses every 6 weeks, with adverse events generally reported as consistent between investigational and placebo groups. (aphis.usda.gov)

Commercially, Elanco is differentiating Befrena on dosing interval, administration, and label flexibility. Company materials say the injection is given in clinic, by or under the supervision of a licensed veterinarian, with a recommended 6- to 8-week dosing interval. AAHA reported that Befrena is the second injectable monoclonal antibody approved in the U.S. for allergic dermatitis in dogs, joining Cytopoint, and noted there are no age or weight restrictions on its use. AAHA also highlighted practical differences in vial presentation and flagged that anti-drug antibodies may reduce response or contribute to immune-mediated adverse reactions, a consideration veterinarians will likely discuss when setting expectations with pet parents. (elanco.com)

Early reaction from veterinarians tied to the launch has been favorable, though it’s worth noting the quoted experts were connected to Elanco as consultants or participants in company programs. In dvm360’s coverage, Tom Lewis, DVM, DACVD, said the product had appeared safe and effective in the two clinical trials he reviewed and in the Early Experience Program, and Jason Pieper, DVM, MS, DACVD, said he had already seen encouraging results, including in a dog that had failed multiple other atopic dermatitis treatments. Another early-use case cited by Elanco involved a Texas dog whose veterinarian reported itch stopped within 24 hours after injection. (dvm360.com)

Why it matters: For veterinary teams, Befrena arrives in a part of practice where case management is rarely simple. AAHA’s 2024 allergic skin disease guidelines stress that atopy is a diagnosis of exclusion, that a minimum dermatologic database is still essential, and that these patients often need lifelong management with strong client communication. In practice, that means Befrena is unlikely to replace workups for ectoparasites, pyoderma, otitis, food allergy, or environmental triggers. Instead, it may give clinicians another tool for dogs needing rapid itch control, longer intervals between injections, or an alternative to existing biologics and oral immunomodulators. It may also create new decision points around sequencing with other therapies, monitoring response over repeated dosing, and discussing cost, adherence, and expectations with pet parents. (abvp.com)

What to watch: The next questions are operational as much as clinical. Elanco has described the rollout as phased and said it is increasing supply as manufacturing scales, so availability may expand gradually rather than all at once. Veterinary professionals will also be watching whether real-world durability matches the labeled 6- to 8-week interval across a broad case mix, how often anti-drug antibodies affect repeat use, and whether Befrena changes competitive dynamics in canine itch management during the 2026 allergy season. (nasdaq.com)